Prominent Gastrointestinal Stromal Tumor Market Trend for 2025: Increasing Focus On Drug Approvals To Drive The Revenues

How Are the key drivers contributing to the expansion of the gastrointestinal stromal tumor market?
The gastrointestinal stromal tumor market is poised for growth due to the increasing prevalence of stomach cancer. Stomach cancer, characterized by the uncontrollable proliferation of malignant cells in the stomach lining, is distinct from gastrointestinal stromal tumors (GISTs), which can also occur in the stomach. However, patients with GISTs are found to be at a higher risk of acquiring additional cancers, such as small bowel adenocarcinoma, when two different tumors coalesce into one. The American Cancer Society, a professional organization based in the U.S., projected that around 26,890 new stomach cancer cases and 10,880 deaths are expected in the U.S. in 2024, constituting 1.5% of all new cancer diagnoses in that year. As such, the increased occurrence of stomach cancer is fueling the growth of the gastrointestinal stromal tumor market. Additionally, the gastrointestinal stromal tumor market is set for growth propelled by the growing demand for precision medicine. Precision medicine offers a personalized approach to healthcare, tailoring decisions, interventions, and therapies based on individual patient attributes, such as genetic information and lifestyle choices. For GISTs, precision medicine employs molecular profiling to pinpoint specific mutations, facilitating the use of targeted therapies like imatinib, improving treatment effectiveness, and reducing side effects via customized interventions. The Personalized Medicine Coalition (PMC), a nonprofit organization based in the U.S., stated in a February 2023 report that personalized medicines constituted 35% of newly approved NMEs in 2021. With 12 new approvals in 2022, these medicines have held at least a quarter of new drug approvals for the past eight years, a significant increase from less than 10% ten years ago. Consequently, the escalating demand for precision medicine is fueling the rise of the gastrointestinal stromal tumor market.

Get Your Gastrointestinal Stromal Tumor Market Report Here:
https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

What growth opportunities are expected to drive the gastrointestinal stromal tumor market's CAGR through 2034?
The market size for gastrointestinal stromal tumor has seen robust growth in the past few years. The market is set to expand from $1.28 billion in 2024 and reach $1.37 billion in 2025, growing at a Compound Annual Growth Rate (CAGR) of 7.2%. The growth during the historic period can be credited to raised awareness and early diagnosis, the advent of targeted therapies, advancements in surgical methodologies, the progression of personalized medicine, and improvements in supportive care.

The market for gastrointestinal stromal tumor is anticipated to witness significant expansion in the upcoming years. The size of the market is projected to reach $1.82 billion in 2029, growing at a compound annual growth rate (CAGR) of 7.4%. This surge during the forecast period can be linked to ongoing research and pharmaceutical advancements, growing focus on patient-specific healthcare, the incorporation of precision medicine into clinical treatment, enhanced availability of targeted therapies, and growth in genomic profiling competencies. The forecast period is expected to see major trends like increased partnerships in research and development, progress in diagnostic technologies, joint research, and clinical trials, heightened emphasis on early detection and diagnosis, and the investigation of combined therapies.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp

What are the most significant trends transforming the gastrointestinal stromal tumor market today?
Leading players in the gastrointestinal stromal tumor market are introducing innovative drugs like QINLOCK (Ripretinib) in an attempt to reach a wider customer base and experience growth in sales and revenue. QINLOCK (Ripretinib) is a prescription medication used for the treatment of advanced gastrointestinal stromal tumor (GIST). For example, in January 2024, the US Food and Drug Administration (FDA), a federal agency based in the US, reported that the CDER novel drug approvals increased from 37 in 2022 to 55 in 2023. Additionally, 20 out of 55, or 36% of the novel drugs approved in 2023 were classified as first-in-class by the CDER.

Which growth-oriented segments of the gastrointestinal stromal tumor market are leading the industry's development?
The gastrointestinal stromal tumor market covered in this report is segmented -

1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
2) By Indication: Stomach, Small Intestine, Others Indications
3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users

Subsegments:
1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens
2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents
3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel Therapies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13248

What regions are leading the charge in the gastrointestinal stromal tumor market?
North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What companies are at the forefront of innovation in the gastrointestinal stromal tumor market?
Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp

What Is Covered In The Gastrointestinal Stromal Tumor Global Market Report?

• Market Size Forecast: Examine the gastrointestinal stromal tumor market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the gastrointestinal stromal tumor market for a structured understanding.
• Key Players Overview: Analyze major players in the gastrointestinal stromal tumor market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the gastrointestinal stromal tumor market.
• Segment Contributions: Evaluate how different segments drive overall growth in the gastrointestinal stromal tumor market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the gastrointestinal stromal tumor market.
• Industry Challenges: Identify potential risks and obstacles affecting the gastrointestinal stromal tumor market.
• Competitive Landscape: Review strategic developments in the gastrointestinal stromal tumor market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.